Hypothesis

Rapamycin extends lifespan by mimicking nutrient scarcity, but it does not engage the mechanosensitive BAG3‑HSPB8‑STUB1 complex that drives selective degradation of tension‑unfolded cytoskeletal proteins. We hypothesize that adding a low‑magnitude, whole‑body vibration (WBV) regimen to rapamycin treatment will activate the integrin‑FAK‑RhoA mechanotransduction axis, leading to BAG3 recruitment, HSPB8 phosphorylation, and STUB1‑mediated ubiquitination of mechanically damaged proteins. This combined activation will increase cargo‑selective autophagy (CASA) while maintaining the bulk autophagy boost from mTOR inhibition, resulting in superior proteostasis, reduced senescence, and a longer lifespan than either rapamycin or WBV alone.

Rationale

• Rapamycin robustly upregulates LC3‑II and ULK1 phosphorylation across tissues, indicating enhanced autophagosome formation, yet no study shows it induces BAG3, HSPB8, or CASA complex assembly {4}.
• Mechanical tension directly recruits the BAG3‑HSPB8‑STUB1 complex to cytoskeletal stress sites (e.g., muscle Z‑disks) where it ubiquitinates tension‑unfolded proteins such as filamin C for selective autophagic clearance {1}.
• Aging shifts the BAG1‑to‑BAG3 balance toward BAG3 under stress, favoring autophagy over proteasomal degradation, but ECM stiffening sustains mTORC1 activity and impairs autophagy; cyclic mechanical stretching reverses this effect {5}, {6}.
• mTOR inhibition and mechanotransduction converge on LC3‑mediated autophagy but diverge in cargo specificity: CASA targets mechanically damaged cytoskeletal proteins, whereas mTOR inhibition clears a broader degradation‑prone proteome {1}.

Thus, rapamycin captures the metabolic stress axis of a "harder life" while WBV captures the mechanical stress axis. Simultaneous activation should engage both axes, providing a more comprehensive proteostatic response.

Predictions

1. Mice receiving rapamycin + WBV will show higher BAG3 protein levels and increased HSPB8 phosphorylation in skeletal muscle and heart compared to rapamycin‑only or WBV‑only groups.
2. Cofractionation assays will reveal greater STUB1‑mediated ubiquitination of tension‑unfolded substrates (e.g., FLNC, α‑actinin) in the combined treatment.
3. Autophagic flux (LC3‑II turnover with lysosomal inhibition) will be elevated in all groups, but the rapamycin + WBV group will exhibit a larger increase in p62/SQSTM1‑dependent selective autophagy markers.
4. Senescence biomarkers (p16^Ink4a^, SA‑β‑gal) will be lowest in the combined group, correlating with improved tissue histology.
5. Median and maximal lifespan will be significantly extended in the rapamycin + WBV cohort relative to each monotherapy and control (p < 0.01, log‑rank test).

Experimental Design

• Animals: C57BL/6J mice, both sexes, n = 30 per group, starting at 6 months of age.
• Groups: (1) Control (vehicle), (2) Rapamycin (14 ppm diet), (3) WBV (30 Hz, 0.3 g, 15 min/day, 5 days/week), (4) Rapamycin + WBV.
• Intervention Duration: Lifelong monitoring; tissue harvests at 12, 18, and 24 months for biochemical assays.
• Readouts: Western blot for BAG3, phospho‑HSPB8, LC3‑II, ULK1‑pS555; co‑immunoprecipitation of BAG3‑HSPB8‑STUB1; ubiquitin‑FLNC immunostaining; lysosomal cathepsin activity; senescence-associated β‑galactosidase staining; grip strength and treadmill endurance; survival analysis.
• Statistical Analysis: Two‑way ANOVA for tissue data with post‑hoc Tukey; Kaplan‑Meier curves with log‑rank test for survival.

Potential Outcomes and Interpretation

If the hypothesis is correct, the combined treatment will demonstrate additive or synergistic activation of both autophagy pathways, leading to reduced accumulation of mechanically damaged proteins, lower senescence, and a measurable lifespan extension. A null result—no additional benefit over rapamycin alone—would suggest that mechanical stimuli cannot further augment the proteostatic state achieved by mTOR inhibition, implying that the nutrient‑stress axis is the dominant determinant of longevity in this context. Either outcome will clarify whether mimicking both metabolic and mechanical dimensions of a "harder life" is necessary to maximize the healthspan benefits of pharmacological aging interventions.